FDA Schedules Adcomm For Pfizer/BioNTech's COVID-19 Booster Shot

Loading...
Loading...
  • The FDA's panel of outside vaccine advisors will meet in two weeks and discuss Pfizer Inc PFE and BioNTech SE's BNTX supplemental application for a booster shot of their COVID-19 vaccine.
  • The Advisory Committee Meeting is scheduled on September 17, just three days before the Biden administration said it would roll out boosters. Regulators received the supplemental application just a week ago.
  • Related: Pfizer, BioNTech Now Seeking Full Approval For Third COVID-19 Vaccine Dose.
  • The announcement for the advisory committee came as Moderna Inc MRNA said it had started the submission process for its booster. 
  • Related: Moderna Seeks FDA Approval For COVID-19 Booster Shot.
  • Pfizer and BioNTech filed for approval based on a Phase III study data where 306 volunteers received a third dose between 4.8 and 8 months after their second shot and saw "robust" antibodies against the original SARS-CoV-2 strain.
  • For Moderna, the first batch of data submitted is from a Phase II trial that tested the 50 µg dose. The current Moderna vaccine is a 100 µg dose.
  • Price Action: PFE stock is up 0.52% at $46.27, while BNTX stock is down 1.07% at $328.94 during the market session on the last check Thursday.
  • Photo by Johaehn from Pixabay
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...